THSTI (Translational Health Science and Technology Institute) & Sphaera Pharma (India), a subsidiary of Sphaera Pharma (Singapore) have received funding from The Wellcome Trust to develop a novel, first-in-class, therapeutic for the treatment of multiple drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis (TB).
THSTI is a society formed by a galaxy of leading science administrators, registered with the Registrar of Societies, Govt. of NCT, Delhi. THSTI addressed public health issues of national priority through various niche research centers. Among those, six intramural centers with interdisciplinary focus, two extramural centers and one partnership center are functioning currently to meet its objectives of contemporary translational research.